Skip to main content
SpringerLink
Log in
Book cover

Yearbook of Intensive Care and Emergency Medicine pp 129–138Cite as

Economic and Social Burden of Severe Sepsis

  • Chapter

  • 1330 Accesses

Part of the book series: Yearbook of Intensive Care and Emergency Medicine ((YEARBOOK,volume 2009))

Abstract

Sepsis is highly prevalent within intensive care units (ICUs) and is associated with elevated rates of morbidity and mortality [1–3], and high costs [4–7]. For these reasons, healthcare providers, managers, government authorities, and insurance companies have focused their attention on strategies that could reduce the economic and social burden of sepsis. In the healthcare system, ICUs consume a considerable amount of resources and have frequently been considered the target for efforts to reduce escalating medical expenses.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Angus DC, Pereira CA, Silva E (2006) Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 6: 207–212

    PubMed  CAS  Google Scholar 

  2. Silva E, Pedro MA (2004) Brazilian Sepsis Epidemiological Study (BASES study). Crit Care 8: R251–260

    Article  PubMed  Google Scholar 

  3. Martin G S, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546–1554

    Article  PubMed  Google Scholar 

  4. Moerer O, Schmid A, Hofmann M, et al (2002) Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 28: 1440–1446

    Article  PubMed  Google Scholar 

  5. Burchardi H, Schneider H (2004) Economic aspects of severe sepsis. A review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics 22: 793–813

    Article  PubMed  Google Scholar 

  6. Edbrooke D, Hibbert C, Ridley S, Long T, Dickie H (1999) The development of a method for comparative costing of individual intensive care units. Anaesthesia 54: 110–120

    Article  PubMed  CAS  Google Scholar 

  7. Lee H, Doig CJ, Ghali WA, Donaldson C, Johnson D, Manns B (2004) Detailed cost analysis of care for survivors of severe sepsis. Crit Care Med 32: 981–985

    Article  PubMed  Google Scholar 

  8. Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM (1999) The patient-related cost of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 27: 1760–1767

    Article  PubMed  CAS  Google Scholar 

  9. Angus DC, Linde-Zwirble WT, Lidicker J, et al (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303–1310

    Article  PubMed  CAS  Google Scholar 

  10. Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I (2003) The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 29: 1464–1471

    Article  PubMed  Google Scholar 

  11. Heyland DK, Kernerman P, Gafni A, Cook DJ (1996) Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Crit Care Med 24: 1591–1598

    Article  PubMed  CAS  Google Scholar 

  12. American Thoracic Society Workshop on Outcomes Research(2002) Understanding costs and cost-effectiveness in critical care. Am J Respir Crit Care Med 165: 540–550

    Google Scholar 

  13. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. Oxford University Press, Oxford

    Google Scholar 

  14. Sefton T, Byford S, McDaid D, Hills J, Knapp M (2002) Making the Most of it: Economic Evaluation in the Social Welfare Field. Joseph Rowntree Foundation, York

    Google Scholar 

  15. Gold MR, Russell LB, Seigel JE, Weinstein MC (1996) Cost-effectiveness in Health and Medicine. Oxford University Press, New York

    Google Scholar 

  16. Braun L, Riedel AA, Cooper LM (2004) Severe sepsis in managed care: analysis of incidence, one-year mortality, and associated costs of care. J Manag Care Pharm 10: 521–530

    PubMed  Google Scholar 

  17. Chalfin DB, Holbein ME, Fein AM, Carlon GC (1993) Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 269: 549–254

    Article  Google Scholar 

  18. Sogayar AM, Machado FR, Rea-Neto A, et al (2008) A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics 26: 425–434

    Article  PubMed  Google Scholar 

  19. Cheng B, Xie G, Yao S, et al (2007) Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 35: 2538–2546

    Article  PubMed  Google Scholar 

  20. Schmid A, Burchardi H, Clouth J, Schneider H (2002) Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ 3: 77–82

    Article  PubMed  CAS  Google Scholar 

  21. Dellinger, RP, Levy, MM, Carlet, JM, et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34: 17–60

    Article  PubMed  Google Scholar 

  22. Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709

    Article  PubMed  CAS  Google Scholar 

  23. Abraham E, Laterre PF, Garg R, et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332–1341

    Article  PubMed  CAS  Google Scholar 

  24. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347: 993–1000

    Article  PubMed  Google Scholar 

  25. Angus DC, Linde-Zwirble WT, Clermont G, et al (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 31: 1–11

    Article  PubMed  Google Scholar 

  26. Dhainaut JF, Payet S, Vallet B, et al (2007) Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care 11:R99

    Article  PubMed  Google Scholar 

  27. Brar SS, Manns BJ (2007) Activated protein C: cost-effective or costly? Crit Care11:164

    Article  PubMed  Google Scholar 

  28. Fowler RA, Hill-Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM (2003) Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 18: 181–191

    Article  PubMed  CAS  Google Scholar 

  29. Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D (2003) Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 18: 217–227

    Article  PubMed  Google Scholar 

  30. Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW (2003)An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. Pharmacoeconomics 21: 1331–1340

    Article  PubMed  Google Scholar 

  31. Shorr AF, Micek ST, Jackson WLJr, Kollef MH (2007) Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Crit Care Med 35: 1257–1262

    Article  PubMed  Google Scholar 

  32. Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, Shapiro N (2008) The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 36: 1168–1174

    Article  PubMed  Google Scholar 

  33. Rivers E, Nguyen B, Havstad S, et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368–1377

    Article  PubMed  CAS  Google Scholar 

  34. Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ (2006) When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med 34: 2738–2747

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Intensive Care Unit, Hospital Albert Einstein Sao Paulo, SP 05651-901, Brazil

    E. Silva

  2. Department of Internal Medicine, Medical Sciences School Universidade do Estado do Rio de, Janeiro, Rio de Janeiro, Brazil

    D. V. Araujo

Authors
  1. E. Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. V. Araujo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care Erasme Hospital, Université libre de Bruxelles, Route de Lennik 808, B-1070, Brussels, Belgium

    Jean-Louis Vincent (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Silva, E., Araujo, D.V. (2009). Economic and Social Burden of Severe Sepsis. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine. Yearbook of Intensive Care and Emergency Medicine, vol 2009. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-92276-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-92276-6_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-92275-9

  • Online ISBN: 978-3-540-92276-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation